38MO IND. 236: A Canadian Cancer Trial Group (CCTG) phase Ib trial of combined CFI-402257 and weekly paclitaxel (Px) in patients with HER2-negative (HER2-) …
Background CFI-402257 (CFI) is a selective oral inhibitor of TTK protein kinase, a critical
regulator of the mitotic spindle assembly checkpoint, is overexpressed in BC and enhances
activity of Px in BC xenografts. Methods Define recommended phase II dose (RP2D) of CFI
in combination with weekly Px using 3+ 3 escalation. Patients with HER2-advanced BC with
adequate organ function, PS= 0-1, previously treated with 1 or more non-taxane
chemotherapy, were eligible. CFI was given on a 2-day on, 5-day off schedule with Px …
regulator of the mitotic spindle assembly checkpoint, is overexpressed in BC and enhances
activity of Px in BC xenografts. Methods Define recommended phase II dose (RP2D) of CFI
in combination with weekly Px using 3+ 3 escalation. Patients with HER2-advanced BC with
adequate organ function, PS= 0-1, previously treated with 1 or more non-taxane
chemotherapy, were eligible. CFI was given on a 2-day on, 5-day off schedule with Px …
